Sagimet Biosciences (SGMT) Enterprise Value (2022 - 2026)

Sagimet Biosciences' Enterprise Value history runs 5 years deep, the most recent figure standing at -$104.5 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 27.69% year-over-year to -$104.5 million in Q1 2026; TTM through Mar 2026 was -$104.5 million, a 27.69% increase from a year earlier, with the FY2025 full-year figure at -$113.1 million, up 25.21% from the prior year.
• Enterprise Value grew to -$104.5 million in Q1 2026 per SGMT's latest filing, from -$113.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$18.5 million in Q2 2023 and bottomed at -$193.7 million in Q1 2024.
• The 5-year median for Enterprise Value is -$116.7 million (2025), against an average of -$116.6 million.
• Across the five-year window, Enterprise Value sank 798.92% in 2024 and climbed 27.69% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$32.3 million in 2022, then sank by 193.39% to -$94.9 million in 2023, then tumbled by 59.38% to -$151.2 million in 2024, then advanced by 25.21% to -$113.1 million in 2025, then rose by 7.59% to -$104.5 million in 2026.
• Per Business Quant, the three latest SGMT Enterprise Value figures stand at -$104.5 million (Q1 2026), -$113.1 million (Q4 2025), and -$116.7 million (Q3 2025).